Inactief instrument

Andere talen BIG CYPR

Aandelen

BCYP

US0891151096

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

UNAUDITED PRO FORMA COMBINED CONDENSED CONSOLIDATED FINANCIAL INFORMATION - Form 8-K	28-10-21
Big Cypress Acquisition Corp.(NasdaqCM:BCYP) dropped from NASDAQ Composite Index	22-10-21
SAB Biotherapeutics, Inc. completed the acquisition of Big Cypress Acquisition Corp. in a reverse merger transaction.	22-10-21
BIG CYPRESS ACQUISITION CORP. : Submission of Matters to a Vote of Security Holders (form 8-K)	21-10-21
Big Cypress Acquisition Corp. Announces Board Changes	21-10-21
Big Cypress Acquisition Corp. : Stockholders Approve Business Combination with SAB Biotherapeutics	21-10-21
SAB Corporate Presentation	15-10-21
BIG CYPRESS ACQUISITION CORP. : Other Events (form 8-K)	13-10-21
R&D Day Presentation	13-10-21
BIG CYPRESS ACQUISITION CORP. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	12-10-21
Big Cypress Acquisition : SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021	06-10-21
Big Cypress Acquisition : SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19	04-10-21
SAB Biotherapeutics : Appoints Russell Beyer Chief Financial Officer	28-09-21
SAB Biotherapeutics: SAB-185 zur Behandlung von COVID-19 erhält positive DSMB-Stellungnahme und erreicht Phase 3 in NIH-gesponserter Studie ACTIV-2	25-09-21
SAB Biotherapeutics : annonce que le SAB-185 a reçu une très bonne évaluation d'un comité de contrôle des données (CICD) et qu'il progresse désormais vers la Phase 3 dans le cadre de l'essai ACTIV-2 sponsorisé par les National Institutes of Health...	25-09-21
SAB Biotherapeutics : anuncia la revisión positiva del DSMB para SAB-185, que pasa a la fase 3 en el ensayo ACTIV-2 patrocinado por los NIH para el tratamiento de la COVID-19	24-09-21
SAB Biotherapeutics : Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19	24-09-21
Big Cypress Acquisition Corp : Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics	23-09-21
Big Cypress Acquisition : SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19	22-09-21
SAB Biotherapeutics : Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza	15-09-21

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen BIG CYPR

Aandelen

BCYP

US0891151096

Andere talen

Filters